Is a complete CSTL research report available?

No complete published report is available for Castle Biosciences, Inc. (CSTL) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Castle Biosciences, Inc. (CSTL)

NASDAQ: CSTL · USD

$26.8

+2.33 (+9.5%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CSTL analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	812.5M
Revenue (ttm)	357.3M
Net income (ttm)	-19.4M
EPS (ttm)	-$0.65
Shares out	30.3M
Volume	716,330
Beta	1.00
Price target	$42.8	+59.7%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 357.3M
Net income (ttm): -19.4M
EPS (ttm): -$0.65
Market cap: 812.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CSTL indicators

Market & fundamental data

Available fields

226

Groups with data

Currency

USD

Showing 226 of 226 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001447362
Company name	Castle Biosciences, Inc.
Country	United States
Country code	US
Cusip	14843C105
Employees	942
Employees Change	59%
Employees Change Percent	6.68
Enterprise value	$582.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Diagnostics & Research
Industry PE	44.15
Industry PE Fwd	26.31
IPO Date	2019-07-25
Isin	US14843C1053
Last refreshed	2026-07-31
Market cap	$812.5M
Market cap category	Small-Cap
Price	$26.79
Price currency	USD
Rev Per Employee	379,276.01x
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	8071
Symbol	CSTL
Website	https://castlebiosciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.39%
EV Sales Forward	1.62x
EV/Sales	1.63x
FCF yield	-0.06%
P/B ratio	1.76x
P/S ratio	2.27x
PS Forward	2.25x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-8.99%
EBITDA Margin	-4.62%
Gross margin	77.26%
Gross Profit	$276M
Gross Profit Growth	-1.58%
Gross Profit Growth Q	16.46%
Gross Profit Growth3 Y	29.23%
Gross Profit Growth5 Y	33.05%
Net Income	$-19.4M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-5.37%
Profit Margin	-5.43%
Profit Per Employee	$-20,610
ROA	-3.63
Roa5y	-5.79
ROCE	-6.36
ROE	-4.2
Roe5y	-7.91
ROIC	-13.48
Roic5y	-41.58

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	65.12%
Cagr3y	16.76%
Cagr5y	-17.12%
EPS Growth Quarters	1
EPS Growth Years	0
FCF Growth Q	-43.32%
OCF Growth	-31.77%
OCF Growth Q	-26.99%
Revenue Growth	3.18x
Revenue Growth Q	20.14x
Revenue Growth Years	8x
Revenue Growth3 Y	28.72x
Revenue Growth5 Y	35.55x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.65
Assets	$561.2M
Cash	$266.8M
Current Assets	$341.1M
Current Liabilities	$56.5M
Debt	$36.7M
Debt Equity	$0.08
Equity	$470M
Interest Coverage	-85.62
Liabilities	$91.1M
Long Term Assets	$220.1M
Long Term Liabilities	$34.6M
Net Cash	$230.2M
Net Cash By Market Cap	$28.33
Net Cash Growth	-3.53%
Net Debt Equity	$-0.49
Tangible Book Value	$374.9M
Tangible Book Value Per Share	$12.29
WACC	9.35

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.04
Inventory Turnover	8.58
Net Working Capital	$22.1M
Quick ratio	5.58
Working Capital	$284.6M
Working Capital Turnover	$1.23

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.6%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	65.07%
200-day SMA	28.84
3Y total return	59.18%
50-day SMA	22.49
50-day SMA vs 200-day SMA	50under200
5Y total return	-60.9%
All Time High	107.7
All Time High Change	-75.12%
All Time High Date	2021-02-10
All Time Low	9.26
All Time Low Change	189.31%
All Time Low Date	2023-06-05
ATR	1.2
Beta	1
Beta1y	0.25
Beta2y	0.48
Ch YTD	-31.13
High	27.13
High52	44.28
High52 Date	2026-01-26
High52ch	-39.5%
Low	24.5
Low52	14.59
Low52 Date	2025-08-04
Low52ch	83.62%
Ma50ch	19.11%
Premarket Change Percent	0.98
Premarket Price	$24.7
Premarket Volume	2,033
Price vs 200-day SMA	-7.1%
RSI	67.22
RSI Monthly	50.6
RSI Weekly	53.6
Sharpe ratio	1.03x
Sortino ratio	1.8
Total Return	-4.6%
Tr YTD	-31.13
Tr1m	10.16%
Tr1w	5.14%
Tr3m	10.52%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	3
Analyst Price Target Top	$47.33
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.41
Earnings Revenue Estimate	86,562,312x
Earnings Revenue Estimate Growth	0.43x
Operating Income	$-32.1M
Operating margin	-8.99
Price target	$42.78
Price Target Change	$59.69
Price Target Change Top	$76.67

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26,797,526%
Float Percent	88.35%
Net Borrowing	-106,000
Shares Insiders	2.55%
Shares Institutions	82.52%
Shares Out	30,329,952
Shares Qo Q	1.71%
Shares Yo Y	4.6%
Short Float	5.31%
Short Ratio	3.98
Short Shares	4.69

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-45.4M
Adjusted OCF	-2,237,000
Average Volume	318,577.15x
Bv Per Share	15.41
CAPEX	$-43.1M
Ch1m	10.16
Ch1w	5.14
Ch1y	65.07
Ch3m	10.52
Ch3y	59.18
Ch5y	-60.9
Ch6m	-31.59
Change	9.53%
Change From Open	9.35
Close	24.46
Days Gap	0.16
Depreciation Amortization	15,592,000
Dollar Volume	19,190,480.7
Earnings Date	2026-07-30
Earnings Time	amc
EBIT	$-32.1M
EBITDA	$-16.5M
EPS	$-0.65
F Score	3
FCF	$-489,000
FCF EV Yield	-0.08x
FCF Per Share	$-0.02
Financing CF	-11,427,000
Fiscal Year End	December
Founded	2,007
Income Tax	$212,000
Investing CF	-51,324,000
Ipr	67.44
Iprfo	33.95
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-30
Last Report Date	2026-06-30
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	27.51
Ma150ch	-2.61%
Ma20	24.28
Ma20ch	10.35%
Net CF	-20,117,000
Next Earnings Date	2026-11-02
Open	24.5
Optionable	Yes
P OCF Ratio	19.06
Position In Range	87.07
Post Close	26.79
Postmarket Change Percent	6.94
Postmarket Price	$28.65
Ppne	118,878,000
Pre Close	24.46
Price Date	2026-07-30
Ptbv Ratio	2.17
Relative Volume	2.25x
Revenue	357,278,000x
SBC By Revenue	12.56x
Share Based Comp	44,871,000
Tax By Revenue	0.06x
Tr6m	-31.59%
Us State	Texas
Volume	716,330

Castle Biosciences, Inc. (CSTL)

Coverage state: Market snapshot only — no published research

Generate the first CSTL analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CSTL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CSTL indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CSTL

Frequently asked questions